Tranexamic acid mediates proinflammatory and anti-inflammatory signaling via complement C5a regulation in a plasminogen activator-dependent manner.

Abstract

BACKGROUND:

Both tissue plasminogen activator (tPA) in the circulation and urokinase (uPA) in tissues cleave plasminogen (PLG) to plasmin to promote clot lysis. Tranexamic acid (TXA) blocks both the tPA-dependent generation of plasmin on blood clots as well as active plasmin binding to polymerized fibrin, and is commonly administered for bleeding in trauma to limit fibrinolysis. In addition to lysing clots, however, active plasmin also cleaves complement proteins, potentially enhancing inflammation. Because TXA does not block uPA-dependent plasmin generation from PLG and instead augments it, we hypothesized that administration of TXA could enhance or inhibit proinflammatory C5a formation in a PLG activator-dependent manner.

METHODS:

Citrate platelet-poor plasma (PPP) and PPP depleted of complement protein C3 or PLG were obtained from healthy donors and commercial sources. Platelet-poor plasma was treated ex vivo with or without TXA and either with or without tPA or with or without uPA. Clotting was then induced by calcium and thrombin in clotted PPP experiments, while unclotted PPP experiments were treated with vehicle controls. C5a levels were measured via enzyme-linked immunosorbent assay. Data were expressed as mean ± SEM.

RESULTS:

Plasmin-mediated fibrinolysis by tPA in clotted PPP led to an approximately threefold increase in C5a production (p < 0.0001), which was significantly inhibited by TXA (p < 0.001). Paradoxically, when fibrinolysis was induced by uPA, TXA treatment led to further increases in C5a production beyond uPA alone (p < 0.0001). Furthermore, clotting was not required for C5a generation from uPA + TXA. C3 depletion had no effect on C5a production, while depletion of PLG eliminated it.

CONCLUSIONS:

Tranexamic acid administration can have proinflammatory or anti-inflammatory effects through regulating C5a generation by plasmin, depending on the predominating PLG activator. Tranexamic acid may cause significant inflammatory C5a elevations in injured tissues by augmenting uPA-mediated plasmin generation in a fibrin-independent manner. In contrast, TXA reduces C5a generation during tPA-mediated fibrinolysis that may reduce inflammatory responses. In vivo validation of these novel ex vivo findings is warranted and may have important clinical consequences.

• Authors: Christopher D Barrett, Hunter B Moore, Yi-Wen Kong, Michael P Chapman, Ganapathy Sriram, Dan Lim, Ernest E Moore, Michael B Yaffe
• Journal: The journal of trauma and acute care surgery (J Trauma Acute Care Surg) Vol. 86 Issue 1 Pg. 101-107 (01 2019) ISSN: 2163-0763 [Electronic] United States
• PMID: 30575685 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, Non-P.H.S.)

Chemical References

• Anti-Inflammatory Agents
• Antifibrinolytic Agents
• Inflammation Mediators
• Tranexamic Acid
• Complement C5a
• Plasminogen
• Thrombin
• Tissue Plasminogen Activator
• Fibrinolysin
• Urokinase-Type Plasminogen Activator

Topics

• Adult
• Anti-Inflammatory Agents (metabolism)
• Antifibrinolytic Agents (administration & dosage, pharmacology)
• Blood Coagulation (drug effects, physiology)
• Complement C5a (drug effects, metabolism)
• Female
• Fibrinolysin (metabolism)
• Fibrinolysis (drug effects, physiology)
• Hemorrhage (drug therapy, etiology)
• Humans
• Inflammation Mediators (metabolism)
• Male
• Middle Aged
• Plasminogen (drug effects, metabolism)
• Signal Transduction (drug effects)
• Thrombin (metabolism)
• Tissue Plasminogen Activator (metabolism)
• Tranexamic Acid (administration & dosage, pharmacology)
• Urokinase-Type Plasminogen Activator (metabolism)
• Wounds and Injuries (complications)